Predictors of the Response to Adalimumab in Rheumatoid Arthritis
NCT00234234
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
200
Enrollment
OTHER
Sponsor class
Conditions
Rheumatoid Arthritis
Interventions
DRUG:
Adalimumab
Sponsor
University Hospital, Rouen